Medical therapies have entered center stage in the treatment of hepatocellular carcinoma (HCC) little more than a year after the positive results of a large phase III trial of sorafenib showed a clear survival benefit with sorafenib. a targeted agent. in this setting. Even though this marks a breakthrough in the treatment of HCC. https://bellfordtoysandhobbiers.shop/product-category/display-figure/